Literature DB >> 30337359

Positive impact of molecular analysis on prognostic scores in essential thrombocythemia: a single center prospective cohort experience.

Damien Luque Luque Paz1,2,3,4, Olivier Mansier4,5,6,7, Jérémie Riou1,8, Carole Conejero9,10, Lydia Roy9,11, Célia Belkhodja4,9,11, Valérie Ugo1,2,3,4, Stéphane Giraudier12,13,14.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30337359      PMCID： PMC6442979          DOI： 10.3324/haematol.2018.197699

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  18 in total

1.  A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.

Authors:  Francesco Passamonti; Jürgen Thiele; Francois Girodon; Elisa Rumi; Alessandra Carobbio; Heinz Gisslinger; Hans Michael Kvasnicka; Marco Ruggeri; Maria Luigia Randi; Naseema Gangat; Alessandro Maria Vannucchi; Andrea Gianatti; Bettina Gisslinger; Leonhard Müllauer; Francesco Rodeghiero; Emanuele S G d'Amore; Irene Bertozzi; Curtis A Hanson; Emanuela Boveri; Filippo Marino; Margherita Maffioli; Domenica Caramazza; Elisabetta Antonioli; Valentina Carrai; Veronika Buxhofer-Ausch; Cristiana Pascutto; Mario Cazzola; Tiziano Barbui; Ayalew Tefferi
Journal:  Blood       Date:  2012-06-26       Impact factor: 22.113

2.  Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

Authors:  Tiziano Barbui; Giovanni Barosi; Gunnar Birgegard; Francisco Cervantes; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Rudiger Hehlmann; Ronald Hoffman; Jean-Jacques Kiladjian; Nicolaus Kröger; Ruben Mesa; Mary F McMullin; Animesh Pardanani; Francesco Passamonti; Alessandro M Vannucchi; Andreas Reiter; Richard T Silver; Srdan Verstovsek; Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

3.  Targeted deep sequencing in polycythemia vera and essential thrombocythemia.

Authors:  Ayalew Tefferi; Terra L Lasho; Paola Guglielmelli; Christy M Finke; Giada Rotunno; Yoseph Elala; Annalisa Pacilli; Curtis A Hanson; Alessandro Pancrazzi; Rhett P Ketterling; Carmela Mannarelli; Daniela Barraco; Tiziana Fanelli; Animesh Pardanani; Naseema Gangat; Alessandro M Vannucchi
Journal:  Blood Adv       Date:  2016-11-22

4.  MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.

Authors:  Paola Guglielmelli; Terra L Lasho; Giada Rotunno; Mythri Mudireddy; Carmela Mannarelli; Maura Nicolosi; Annalisa Pacilli; Animesh Pardanani; Elisa Rumi; Vittorio Rosti; Curtis A Hanson; Francesco Mannelli; Rhett P Ketterling; Naseema Gangat; Alessandro Rambaldi; Francesco Passamonti; Giovanni Barosi; Tiziano Barbui; Mario Cazzola; Alessandro M Vannucchi; Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2017-12-09       Impact factor: 44.544

5.  Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome.

Authors:  Damien Luque Paz; Aurélie Chauveau; Françoise Boyer; Caroline Buors; Laura Samaison; Laurane Cottin; Valérie Seegers; Claude Férec; Cédric Le Maréchal; Paul Gueguen; Eric Lippert; Jean-Christophe Ianotto; Valérie Ugo
Journal:  Genes Chromosomes Cancer       Date:  2017-02-01       Impact factor: 5.006

6.  Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia.

Authors:  Alberto Alvarez-Larrán; Alicia Senín; Concepción Fernández-Rodríguez; Arturo Pereira; Eduardo Arellano-Rodrigo; Montse Gómez; Francisca Ferrer-Marin; Joaquín Martínez-López; Laura Camacho; Dolors Colomer; Anna Angona; Blanca Navarro; Francisco Cervantes; Carlos Besses; Beatriz Bellosillo; Juan Carlos Hernández-Boluda
Journal:  Br J Haematol       Date:  2017-05-23       Impact factor: 6.998

7.  Mutations and prognosis in primary myelofibrosis.

Authors:  A M Vannucchi; T L Lasho; P Guglielmelli; F Biamonte; A Pardanani; A Pereira; C Finke; J Score; N Gangat; C Mannarelli; R P Ketterling; G Rotunno; R A Knudson; M C Susini; R R Laborde; A Spolverini; A Pancrazzi; L Pieri; R Manfredini; E Tagliafico; R Zini; A Jones; K Zoi; A Reiter; A Duncombe; D Pietra; E Rumi; F Cervantes; G Barosi; M Cazzola; N C P Cross; A Tefferi
Journal:  Leukemia       Date:  2013-04-26       Impact factor: 11.528

8.  Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients.

Authors:  Xénia Cabagnols; Fabrizia Favale; Florence Pasquier; Kahia Messaoudi; Jean Philippe Defour; Jean Christophe Ianotto; Christophe Marzac; Jean Pierre Le Couédic; Nathalie Droin; Ilyas Chachoua; Remi Favier; M'boyba Khadija Diop; Valérie Ugo; Nicole Casadevall; Najet Debili; Hana Raslova; Christine Bellanné-Chantelot; Stefan N Constantinescu; Olivier Bluteau; Isabelle Plo; William Vainchenker
Journal:  Blood       Date:  2015-10-08       Impact factor: 22.113

9.  Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.

Authors:  Mandy Brecqueville; Jérôme Rey; François Bertucci; Emilie Coppin; Pascal Finetti; Nadine Carbuccia; Nathalie Cervera; Véronique Gelsi-Boyer; Christine Arnoulet; Olivier Gisserot; Denis Verrot; Borhane Slama; Norbert Vey; Marie-Joelle Mozziconacci; Daniel Birnbaum; Anne Murati
Journal:  Genes Chromosomes Cancer       Date:  2012-04-09       Impact factor: 4.263

10.  Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.

Authors:  D Pietra; E Rumi; V V Ferretti; C A Di Buduo; C Milanesi; C Cavalloni; E Sant'Antonio; V Abbonante; F Moccia; I C Casetti; M Bellini; M C Renna; E Roncoroni; E Fugazza; C Astori; E Boveri; V Rosti; G Barosi; A Balduini; M Cazzola
Journal:  Leukemia       Date:  2015-10-09       Impact factor: 11.528
View more
  3 in total

1.  Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation.

Authors:  Damien Luque Paz; Rébecca Jouanneau-Courville; Jérémie Riou; Jean-Christophe Ianotto; Françoise Boyer; Aurélie Chauveau; Maxime Renard; Jean-Claude Chomel; Emilie Cayssials; Maria-Pilar Gallego-Hernanz; Cédric Pastoret; Anne Murati; Frédéric Courtier; Marie-Christine Rousselet; Isabelle Quintin-Roué; Laurane Cottin; Corentin Orvain; Sylvain Thépot; Jean-Marie Chrétien; Yves Delneste; Norbert Ifrah; Odile Blanchet; Mathilde Hunault-Berger; Eric Lippert; Valérie Ugo
Journal:  Blood Adv       Date:  2020-10-13

2.  Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world setting.

Authors:  Tomoki Ito; Yoshinori Hashimoto; Yasuhiro Tanaka; Aya Nakaya; Shinya Fujita; Atsushi Satake; Takahisa Nakanishi; Akiko Konishi; Masaaki Hotta; Hideaki Yoshimura; Kazuyoshi Ishii; Akiko Hashimoto; Toshinori Kondo; Hiromi Omura; Isaku Shinzato; Takayuki Tanaka; Shosaku Nomura
Journal:  Eur J Haematol       Date:  2019-06-17       Impact factor: 2.997

Review 3.  Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses.

Authors:  Vibe Skov
Journal:  Cancers (Basel)       Date:  2020-08-06       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.